Abstract library

53 results for "Flushing".
#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Julian Gertner
Keywords: telotristat
#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Simone Leyden
Authors: Leyden S, Cummins M, Wakelin K, ...
#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...
#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Diego Carrillo
#2818 Is It That Rare?
Introduction: Carcinoid heart disease (CHD) is a rare and unique manifestation, It present in 50% of CS
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Saleha Babli
Authors: Babli S, Alzahrani W, Aldawish M, ...
#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Hearn K, Teo L, Bernstone G, Johnson S, ...
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#75 Carcinoid and carcinoid syndrome: analysis of 110 cases from a single insitute
Introduction: Carcinoid syndrome (CS) often presents with flushing, diarrhea and carcinoid heart disease (CHD).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Emilio Bajetta
#98 Long-term follow-up analysis of lung carcinoid tumors: retrospective monoinstitutional evaluation
Introduction: Detection of prognostic factors of bronchopulmonary carcinoid (BPCs) tumors is complicated due to the rare frequency of this malignancy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Emilio Bajetta